Medical treatment for gastro-entero-pancreatic neuroendocrine tumours

被引：0

作者：

Rossana Berardi ^{[1
]}

Francesca Morgese ^{[1
]}

Mariangela Torniai ^{[1
]}

Agnese Savini ^{[1
]}

Stefano Partelli ^{[2
]}

Silvia Rinaldi ^{[1
]}

Miriam Caramanti ^{[1
]}

Consuelo Ferrini ^{[1
]}

Massimo Falconi ^{[2
]}

Stefano Cascinu ^{[1
]}

机构：

[1] Department of Medical Oncology, Università Politecnica delle Marche

[2] Chirurgia del Pancreas, Ospedale San Raffaele IRCCS, Università Vita e Salute

来源：

World Journal of Gastrointestinal Oncology | 2016年 / 04期

关键词：

Neuroendocrine neoplasms of the gastro-entero-pancreatic system; Chemotherapy; Targeted agents; Somatostatin analogues; Everolimus; Sunitinib;

D O I：

暂无

中图分类号：

R735 [消化系肿瘤];

学科分类号：

100214 ;

摘要：

Gastro-entero-pancreatic neuroendocrine neoplasms(GEPNENs) represents a various family of rare tumours. Surgery is the first choice in GEP-NENs patients with localized disease whilst in the metastatic setting many other treatment options are available. Somatostatin analogues are indicated for symptoms control in functioning tumours. Furthermore they may be effective to inhibit tumour progression. GEP-NENs pathogenesis has been extensively studied in the last years therefore several driver mutations pathway genes have been identified as crucial factors in their tumourigenesis. GEP-NENs can over-express vascular endothelial growth factor(VEGF), basic-fibroblastic growth factor, transforming growth factor(TGF-α and-β), platelet derived growth factor(PDGF), insulin-like growth factor-1(IGF-1) and their receptors PDGF receptor, IGF-1 receptor, epidermal growth factor receptor, VEGF receptor, and c-kit(stem cell factor receptor) that can be considered as potential targets. The availability of new targeted agents, such as everolimus and sunitinib that are effective in advanced and metastatic pancreatic neuroendocrine tumours, has provided new treatment opportunities. Many trials combing new drugs are ongoing.

引用

页码：389 / 401

页数：13

共 68 条

[11] Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1-5: Development and Immunohistochemical Application in Neuroendocrine Tumors[J] . Schmid,Herbert A,Lambertini,Chiara,Van Vugt,Harmke H,Barzaghi-rinaudo,Patrizia,Sch?fer,Judith,Hillenbrand,Rainer,Sailer,Andreas W,Kaufmann,Martina,Nuciforo,Paolo.Neuroendocrinology . 2012 (3)
[12] Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors .2 Hee Sung Kim,Hye Seung Lee,Woo Ho Kim. CANCER RESEARCH AND TREATMENT . 2011
[13] WHO Classification of Tumours of the Digestive System .2 Rindi,G,Arnold,R,Bosman,F. T,Capella,C,Kilmstra,D. S,Kloppel,G,Komminoth,P,Solcia,E. Lyon, France . 2010
[14] Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment .2 Reubi Jean Claude. Neuroendocrinology . 2004
[15] Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b .2 James C. Yao,Alex,ria Phan,Paulo M. Hoff,Helen X. Chen,Chusilp Charnsangavej,Sai-Ching J. Yeung,Kenneth Hess,Chaan Ng,James L. Abbruzzese,Jaffer A. Aja. J. Clin. Oncol . 2008
[16] Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas .2 Bettina Papouchado,Lori A Erickson,Audrey L Rohlinger,Timothy J Hobday,Charles Erlichman,Matthew M Ames,Ricardo V Lloyd. Modern Pathology . 2005
[17] A prospective, multi-institutional phaseⅡstudy of GW786034(pazopanib) and depot octreotide(sandostatin LAR) in advanced low-grade neuroendocrine carcinoma(LGNEC) .2 Phan AT,Yao JC,Fogelman DR,et al. J Clin Oncol . 2010
[18] Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
Brixi-Benmansour, Hedia
Jouve, Jean-Louis
Mitry, Emmanuel
Bonnetain, Franck
Landi, Bruno
Hentic, Olivia
Bedenne, Laurent
Cadiot, Guillaume
[J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 (11) : 912 - 916
[19] Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study[J] . The Lancet . 2011 (9808)
[20] Hallmarks of Cancer: The Next Generation[J] . Douglas Hanahan,Robert A. Weinberg.Cell . 2011 (5)

← 1 2 3 4 5 6 7 →